Related Experiment Videos
Chemosensitivity study of urological malignancies using a novel dye-exclusion method
K Naito1, H Hisazumi, S Mihara
1Department of Urology, School of Medicine, Kanazawa University, Japan.
Cancer Chemotherapy and Pharmacology
|January 1, 1987
Summary
This study assessed anticancer drug sensitivity in urothelial transitional-cell carcinomas and renal-cell carcinomas using a novel dye-exclusion method. Urothelial tumors showed higher sensitivity at peak drug concentrations, suggesting potential benefits from high-dose intra-arterial or intravesical chemotherapy.
Area of Science:
- Urology
- Medical Oncology
- Pharmacology
Background:
- Urological malignancies present diverse challenges in chemotherapy response.
- Accurate prediction of tumor chemosensitivity is crucial for effective treatment strategies.
Purpose of the Study:
- To evaluate the chemosensitivity of various urological cancers to common anticancer drugs.
- To compare drug sensitivity at different concentration levels and assess treatment implications.
Main Methods:
- A novel dye-exclusion method was employed to determine tumor chemosensitivity.
- Chemosensitivity assays were performed on urothelial transitional-cell carcinomas, renal-cell carcinomas, testicular tumors, and Wilms' tumors.
- Drug sensitivity was assessed at 10% of peak plasma concentration and at peak plasma concentration.
Main Results:
- Urothelial transitional-cell carcinomas demonstrated significantly higher sensitivity to cis-platinum, adriamycin, and carboquone at peak plasma concentrations compared to 10% levels (P < 0.01).
- Renal-cell carcinomas showed low sensitivity (38%) even at peak drug concentrations.
- A modified human tumor clonogenic assay corroborated the observed trends in tumor chemosensitivity.
Conclusions:
- Urothelial transitional-cell carcinomas may respond favorably to high-concentration chemotherapy regimens, such as intra-arterial infusion and intravesical instillation.
- The findings support the use of targeted drug delivery methods for enhancing treatment efficacy in specific urological cancers.